Acrux Ltd
Company Profile
Business description
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline includes Lenzetto, Evamist, Testosterone Topical Solution, and others.
Contact
103-113 Stanley Street
West Melbourne
MelbourneVIC3003
AUST: +61 383790100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
36
Stocks News & Analysis
stocks
Weekly Earnings Wrap: CBA, CSL, MQG and more
stocks
ASX player rallies on small guidance upgrade
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.80 | 66.60 | -0.72% |
| CAC 40 | 8,300.14 | 40.42 | -0.48% |
| DAX 40 | 24,881.37 | 28.68 | 0.12% |
| Dow JONES (US) | 49,451.98 | 669.42 | -1.34% |
| FTSE 100 | 10,390.27 | 12.17 | -0.12% |
| HKSE | 26,567.12 | 465.42 | -1.72% |
| NASDAQ | 22,597.15 | 469.32 | -2.03% |
| Nikkei 225 | 56,941.97 | 697.87 | -1.21% |
| NZX 50 Index | 13,198.18 | 333.30 | -2.46% |
| S&P 500 | 6,832.76 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,917.60 | 55.30 | -0.62% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |